Aardvark Therapeutics adds David Zhang to its board

Aardvark Therapeutics, Inc. (Nasdaq: AARD) announced the appointment of David Zhang, Ph.D., MBA, to its board of directors, effective October 7, 2026. Zhang will serve as an independent director.

Zhang currently serves as Chief Strategy Officer of Abivax S.A., where he has overseen biometrics, regulatory affairs, quality assurance, and health economics. He led the biometrics team through topline readouts of two pivotal Phase 3 trials of obefazimod in ulcerative colitis.

From 2021 to 2024, Zhang was Senior Vice President of Biometrics and Data Management at Alumis Inc., where he was a founding executive and helped the company through its initial public offering. Before that, he served as Vice President and Head of Biometrics, Data Science and Digital Health at MyoKardia, Inc., overseeing the pivotal trial design, readout, and New Drug Application submission for CAMZYOS® (mavacamten) prior to MyoKardia's acquisition by Bristol Myers Squibb.

Earlier in his career, Zhang held leadership roles at Roche Sequencing Solutions and Genentech/Roche over 15 years, and statistician roles at Eli Lilly and Company and Abbott Laboratories.

"Aardvark is at a pivotal moment, with important decisions ahead for ARD-101," Zhang said. "I look forward to working with Tien and the Board to help navigate the regulatory landscape and shape the next phase of development for people living with Prader-Willi Syndrome."

Zhang holds a Ph.D. in biostatistics from the UCLA Fielding School of Public Health and an executive MBA from the Kelley School of Business at Indiana University. He completed postdoctoral research in statistical genetics at Columbia University.

You May Also Be Interested In

• Nuwellis to hold advisory board meeting for pediatric CRRT system
• Entera Bio to present EB613 Phase 3 study design at ASBMR meeting
• Scholar Rock resubmits SMA drug application to European regulators